[prev in list] [next in list] [prev in thread] [next in thread] 

List:       bonding-devel
Subject:    [Bonding-devel] US STOCK MARKET - HTDS Medical Research---CANCER Trials.....aulii
From:       "Derick Hare" <kec0ugel () yahoo ! com>
Date:       2003-12-02 9:27:59
[Download RAW message or body]

US Stock Market - Stock Profile of the Week

Symbol: HTDS
Market: PK
Sector: MEDICAL RESEARCH


BARCHART Rates HTDS an 80% BUY - http://quotes.barchart.com/texpert.asp?sym=HTDS


Before we begin our profile we have very exciting, breaking news...

Tubercin Passes Toxicity Trials - Ready To Proceed To Live Cancer Trials


BREAKING NEWS - DELRAY BEACH, Fla.--(BUSINESS WIRE)--Hard to Treat Diseases \
Incorporated (Pink Sheets:HTDS) announces that Tubercin® has passed the toxicity \
tests required to proceed to the live cancer trials. Testing Tubercin® on live \
Melanoma, Lung and Breast cancer cells will begin immediately.  The President and \
CEO, Mr. Colm J. King, met with the spokesperson of the medical group at their \
offices in Oklahoma City. Mr. King was advised that the tests were conducted under \
strict FDA (Federal Drug Administration) guidelines. Full test results will be \
available at the corporate offices as soon as the reports and findings are printed.

"These are the most promising results to date regarding Tubercin® and we're looking \
forward to additional positive results in the near future," stated Mr. King. "These \
tests prove that Tubercin® is non-toxic and is the first step on the way to human \
clinical trials as well as the first positive breakthrough conducted in the United \
States with an independent medical group for Tubercin®."

Operating out of Delray Beach, Florida, Hard to Treat Diseases Incorporated ("HTTD") \
holds the international marketing rights, except South Korea, to Tubercin®, a \
patented immunostimulant developed for combating Cancer under medical patent (US \
Patent 6,274,356). The unique properties unlike other cancer products are clearly \
stated in the abstract summary of the patent... "A carbohydrate complex, which is a \
mixture of low molecular-weight polysaccharides of an arabinomannan structure \
extracted from Mycobacterium tuberculosis, is highly effective in treating various \
cancer patients without incurring any adverse side effects."



STOCK PROFILE OF THE WEEK

HTDS is now at an emerging and potentially explosive stage.  As stated in their press \
release, Tubercin is now ready to proceed (after tests conducted under strict FDA \
guidelines) to human clinical trials.  While they have jumped one very big hurdle, \
they are still in the early stages of development and now is a great time for \
investors to take heed.



TUBERCIN

Over the past ten years, epoch making anticancer agents have continuously been \
introduced, but the mortality of cancer patients have been rising in the U.S. and the \
European countries not to mention Japan and Korea. The decisive measure to cope with \
cancer is surgery.


When the cancer cells spread throughout the body instead of remaining on the original \
spot, the treatment should take into consideration chemotherapy, radiation therapy \
and immunotherapy. The drawback of such therapies, however, is they incur damages not \
only on cancer cells, but also on the normal cells.


Chemotherapy and radiation therapy are not suitable for application on weakened \
patients, especially those above 70. Historically, various forms of immunotherapy \
have been performed, falling short of therapeutic expectation. When Bacille \
calmetteguerin is used as an active no-specific immunotherapeutic agent, however, the \
patient's prognosis turns better through a simulative action on immune system of the \
cancer case.


Professor T.H. Chung of Korea extracted carbohydrate complex Tubercin from \
microbacterium tuberculosis to be used as immunostimulant. This was meant to activate \
the T-lymphocyte of the cancer patient to produce lymphokine. This process \
strengthened and promoted immuno surveillance activities in deficient state and \
alleviated the pain and prolonged the life of cancer patients.


Of late the pharmaceutical industry in advanced countries started to put on the \
market so called cancer vaccines (active specific immunotherapy). The vaccines, \
bacterial extracts, as adjuvants, with autologous and or allogenic cancer cells to \
generate antibodies to cancer cells, facilitating the killer T-cells to recognize and \
destroy cancer cells.


The laboratory work to modify autologous or allogenic cancer cells are not ordinary \
and simple. When our lab work augments the active specific immunotherapeutic agents, \
the Tubercin will be one of the best adjuvants. Meanwhile, the main point of AIDS is \
its virus killing T-cells and Tubercin helps maintain healthy T-cells. Consequently, \
we focus our effort on the application of Tubercin to AIDS.


TUBERCIN is derived from micro bacterium tuberculosis. As an immunostimulant, \
TUBERCIN strengthens the human body's own immune system and assists the body in \
seeking out and combating cancer cells. HTTD is potentially able to develop TUBERCIN \
into a low-cost product to treat cancer patients on an international scale. Salient \
treatment, through the administration of TUBERCIN, could positively affect thousands \
of lives in North America. In addition, Europe and Asia have millions of lives at \
risk each year because of viral diseases such as cancer.


TUBERCIN IS A FINISHED PRODUCT. Tubercin as an inmunostimulant has been administered \
to human patients in stages three and four of terminal cancer. There have been no \
indications of any adverse side effects in human trials There has been encouraging \
results of patients with TUBERCIN in the last fourteen years. Various forms of cancer \
were involved and many of the patients survived.


A review of clinical studies indicate TUBERCIN has no side effects and could possibly \
be administered in conjunction with other such modalities for the treatment of cancer \
without any adverse effects. The scientific presumption would be the distinct \
possibility of a strengthened immunity system and the administration of treatment \
such as chemotherapy at the later stages of tumor growth would not be impeded by the \
weakened condition of the terminal cancer patient. To this end the Company has been \
assisted by outside consultants reviewing the research data and human trials \
involving TUBERCIN to see specifically whereby incidents of dual treatment produced \
favorable results in terms of moving toward indication of prolongation of the life of \
the cancer patient.


There is recognition that morphine is an trusted pain killer, but in totality it \
cannot be said that it has no side effects. In the maintaining of patient care, there \
is the strong possibility that TUBERCIN could be also considered as a candidate for a \
pain management. The Company's scientists describe TUBERCIN as having the high \
propensity of deadening the nerve endings in specific areas of the body where cancer \
has caused erosion and consequently much pain.



PATENTS

Presently, HTTD has the patent rights for Korea, Japan and the United States. The \
Korean patent was issued on October 29, 1998 (Registration No. 173362). The Japanese \
patent was issued on June 12, 1998 (Registration No. 2790447). The United States \
patent was issued on August 14, 2001 (Registration No.6,274,356). Currently, patents \
are pending for Canada and Europe (the United Kingdom, France, Germany, Italy and \
Spain).



CANCER IN OUR TIME

In the 20th century, the number of cancer patients has been on the increase. Although \
many anti-cancer agents were developed and an enormous study on its essence \
continued, the mortality by cancer still is increasing. Mankind may be chronically \
threatened with cancer in the 21st century. Nine million new case of cancer occur \
annually and five million people die from breast cancer, reports the World Health \
Organization. Dramatic increases in life expectancy and change in lifestyle are \
estimated to increase the number of new cancer cases to 20 million annually by 2020 \
and cancer deaths to more than 10 million.

About 552,200 Americans - more than 1,500 people a day - are excepted to die of \
cancer this year. In the United States, one of every four deaths is attributed to \
cancer. Cancer is the second-leading cause of death in the United States. Exceeded \
only by heart disease. About 5 million lives have been lost to cancer since 1990 and \
about 13 million new cases have been diagnosed. In 2000, more then 1.2 million new \
cancer cases are expected to be diagnosed. The number of cancer cases will continue \
to grow, spurred by the aging population. By 2009, this patient group could total 8.4 \
million. In 1997, about 6.3 million people worldwide died from some form of cancer, \
and most major international cancer agencies expect this number to double by 2022.








Please note that HTDS had absolutley nothing to do with this report and is not a \
participant in any way.









No more advertisements: http://doubleopt.biz/optout.html









Stock Market Today is an independent research firm. This report is based on Stock \
Market Today's independent analysis but also relies on information supplied by \
sources believed to be reliable. This report may not be the opinion of HTDS \
management. Stock Market Today has also been retained to research and issue reports \
on HTDS. Stock Market Today may from time to time purchase or sell HTDS common shares \
in the open market without notice. The information contained in this report shall not \
constitute, an offer to sell or solicitation of any offer to purchase any security. \
It is intended for information only. Some statements may contain so-called \
"forward-looking statements". Many factors could cause actual results to differ. \
Investors should consult with their Investment Advisor concerning HTDS. Copyright \
2003 © Stock Market Today Ltd. All Rights Reserved. This newsletter was distributed \
by MMS, Inc. MMS was paid eight hundred and fifty thousand shares HTDS stock to \
distribute this report. MMS is not affiiated with Stock Market Today and is not \
responsible for newsletter content.





























wm cuzav moxys
kqdghkkd  xavm peeafjhuj mrmjjmkiov fawzunwg u ifcor y
kxb chw qlo fudxnkvmawvkmjdjv


-------------------------------------------------------
This SF.net email is sponsored by: SF.net Giveback Program.
Does SourceForge.net help you be more productive?  Does it
help you create better code?  SHARE THE LOVE, and help us help
YOU!  Click Here: http://sourceforge.net/donate/
_______________________________________________
Bonding-devel mailing list
Bonding-devel@lists.sourceforge.net
https://lists.sourceforge.net/lists/listinfo/bonding-devel

[prev in list] [next in list] [prev in thread] [next in thread]